Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

View Full Paper
Ask AI
Bookmark
Share

Authors

FZFatima Tuz ZahraUniversity of South FloridaDDDaniel DeavilaMoffitt Cancer CenterCBCeleste BelloMoffitt Cancer Center

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows reduced progression-free survival in high-risk aggressive B-cell lymphoma patients treated with bispecific antibodies, suggesting careful patient selection may be needed.

Key Points

  • To evaluate the real-world efficacy of epcoritamab and glofitamab in relapsed/refractory aggressive B-cell lymphoma.
  • Conducted a single-center retrospective analysis at Moffitt Cancer Center
  • Included patients with histologically confirmed B-cell non-Hodgkin lymphoma
  • Analyzed outcomes based on treatment exposure and survival status
  • Overall response rate for the cohort was 37% with complete response at 25%
  • Median progression-free survival was 3.1 months for all patients
  • Inpatient status at bispecific antibody initiation correlated with poor survival outcomes

Cite This Study

Zahra et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db8dhttps://doi.org/10.1182/blood-2025-2767
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  2. 2Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study2025 · 1 citations
  3. 3Real-world outcomes of epcoritamab vs glofitamab in relapsed/refractory diffuse large B-cell lymphoma: A TriNetX retrospective study.2026
  4. 4Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing2026
  5. 5Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma2025